Scienture Holdings, Inc. (SCNX) · Nov 19, 2026 · Earnings
Miss — Diluted EPS $(3.76) vs ~$1.57 consensus; revenue $1.25M vs ~$1.22M
Scienture’s Q3 earnings show rapid revenue growth from REZENOPY and Arbli, but a much larger-than-expected loss keeps profitability elusive.
Scienture is transitioning from a development-stage specialty-pharma company into a commercial business built around two FDA-approved products: Arbli, its liquid losartan product, and REZENOPY, launched in August 2026 for opioid-overdose treatment. The launch was already partly visible before this filing: the company had disclosed preliminary Q3 revenue of roughly $1.22 million and the REZENOPY launch in October.
Commercial traction is real and slightly ahead of the near-term bar. Q3 revenue reached $1.25 million, up 112.6% year over year and roughly 265% sequentially, with about $925,000 coming from initial REZENOPY wholesale shipments. The result was modestly above the published revenue expectation of approximately $1.22 million, confirming that the second product is beginning to broaden the revenue base rather than merely shifting sales between channels.
| Metric | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Revenue (Income Statement) | $1.25M (+112.6%) | $0.59M | ~$1.22M |
| Gross profit (Income Statement) | $1.02M (+77.5%) | $0.57M | |
| Diluted EPS (Income Statement) | $(3.76) | $(4.76) | ~$(1.57) |
| Operating loss (Income Statement) | $(5.72M) | $(4.36M) | |
| Cash and equivalents (Balance Sheet) | $4.75M | $6.66M |
The earnings miss is the more important signal for the business. The $3.76 per-share loss was far worse than the roughly $1.57 consensus loss, while the operating loss widened to $5.72 million despite the revenue ramp. Operating expenses rose to $6.74 million, including higher professional fees and research-and-development spending. That means the commercial launch is generating gross profit, but not yet enough operating leverage to support the company’s stated goal of profitability in 2027.
The distribution story is improving, but remains early and execution-dependent. Scienture says REZENOPY has reached a direct channel serving approximately 2,000 opioid-treatment clinics and addiction-treatment centers, while it continues pursuing government distribution relationships. 〔0〕 That expands the potential customer base, but the filing reports access and initial orders—not recurring demand, formulary wins, or a proven path to scale.
Funding remains part of the operating story. Cash and equivalents fell to $4.75 million from $6.66 million at year-end, while the balance sheet now includes roughly $10.8 million of note debt and current liabilities rose sharply. The recent 10-Q says continued operations depend on product adoption and additional capital, despite management’s view that cash, commercial revenue and planned financing can fund operations for at least twelve months.
Bottom line: Scienture has validated the first step of its commercial transition: REZENOPY is adding meaningful revenue and gross profit. But the much larger-than-expected loss and ongoing capital needs mean the quarter advances the launch story without yet proving the profitability story.
Q4 results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!